AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CHARLESTON, S.C. -- Once-daily treatment with valacyclovir for the suppression of genital herpes caused by herpes simplex virus type-2 was well-tolerated for up to 20 months in a recent study.
Previously, data were available only for up to 12 months of daily valacyclovir use, Zane A. Brown, M.D., of the University of Washington, Seattle, and his colleagues reported in a poster at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology.
For the current study, which was supported by GlaxoSmithKline Inc., 1,484 serodiscordant, heterosexual, monogamous couples were enrolled, and the seropositive partners was randomized to receive either placebo or 500 mg/day of valacyclovir for 8 months.
The results of this double-blind phase, which were previously reported by the investigators, showed that the treatment significantly reduced the risk of genital herpes transmission.
Following the double-blind phase, 1,018 of the 1,484 participants treated in the double-blind phase entered an open-label suppression phase of the study, which provided 12 months of suppressive therapy with 500 mg/day of valacyclovir. Patients in this phase were evaluated every three months for laboratory values and adverse events.
...